PFM Health Sciences’s Labcorp LH Stock Holding History

PFM Health Sciences’s Portfolio LH Stock Details LH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-261,900	Closed	-$53M	–	93
2022 Q4	$53M	Buy	+261,900	New	+$51.2M	1.9%	13

Other funds holding LH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

PFM Health Sciences's LH Position: Q1 2023 in Review

PFM Health Sciences sold out of Labcorp (LH) in Q1 2023, closing a stake of 15,785 shares — an estimated $3.19M sold.

PFM Health Sciences first reported a position in LH in Q2 2020 and held it in 5 quarters. The position peaked at $51.5M in Q2 2020. 940 funds tracked by Wall St. Rank hold LH as of Q1 2023.

PFM Health Sciences reported no remaining Labcorp position as of Q1 2023 after selling out during the quarter.
PFM Health Sciences sold 15,785 Labcorp shares in Q1 2023, an estimated $3.19M.
PFM Health Sciences first reported a position in Labcorp in Q2 2020 and held it in 5 quarters.
PFM Health Sciences's Labcorp position peaked at $51.5M in Q2 2020.
940 funds tracked by Wall St. Rank held Labcorp as of Q1 2023.

Based on PFM Health Sciences's 13F filing for Q1 2023, filed 15 May 2023.